Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Narsis Attar, Rajib Shome, Mehmet Samur, Joshua Gustine, Charlotte Graham, Kathleen ME Gallagher, Agustin Busse, Deshea L Harris, Diana Cirstea, Andrew Yee, Andrew Branagan, Marcela Maus, Matthew Frigault, Nikhil Munshi, Adam Sperling, Noopur Raje

Blood (2025) 146 (Supplement 1): 5764.

https://doi.org/10.1182/blood-2025-5764

Published: 2025

Journal Articles

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Blood (2025) 146 (Supplement 1): 2392.

https://doi.org/10.1182/blood-2025-2392

Published: 2025

Journal Articles

Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5824.

https://doi.org/10.1182/blood-2025-5824

Published: 2025

Journal Articles

Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.

Joshua Gustine, Narsis Attar, Benjamin Puliafito, Diana Cirstea, Andrew Branagan, Marcela Maus, Matthew Frigault, Andrew Yee, Noopur Raje

Blood (2025) 146 (Supplement 1): 2243.

https://doi.org/10.1182/blood-2025-2243

Published: 2025

Journal Articles

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Hang Quach, Rakesh Popat, Wenming Chen, Mary Kwok, Andrew Yee, Zhongxing Jiang, Flávia Xavier, Natalie Callander, Man Yuk Ho, Susan Bal, Michael Low, Douglas Sborov, Gabriel Man, Huan Cheng, Adam Idoine, Xin Wang, Amit Agarwal, Binod Dhakal

Blood (2025) 146 (Supplement 1): 102.

https://doi.org/10.1182/blood-2025-102

Published: 2025

Journal Articles

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 250.

https://doi.org/10.1182/blood-2025-250

Published: 2025

Journal Articles

Immune aging and macrophage inhibitory factor (MIF) – mediated stromal rewiring drives pre-malignant evolution in smoldering multiple myeloma

Rajib Shome, Srikanth Talluri, Diana Cirstea, Rie Matsubara, Farah Rexha, Advait Joshi, Andrew Yee, Nikhil Munshi, Mehmet Samur, Noopur Raje

Blood (2025) 146 (Supplement 1): 3952.

https://doi.org/10.1182/blood-2025-3952

Published: 2025

Journal Articles

Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma

Rajib Shome, Mehmet Samur, Srikanth Talluri, Rie Matsubara, Advait Joshi, Farah Rexha, Diana Cirstea, Andrew Yee, Nikhil Munshi, Noopur Raje

Blood (2025) 146 (Supplement 1): 5735.

https://doi.org/10.1182/blood-2025-5735

Published: 2025

Journal Articles

Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma

Blood (2025) 146 (Supplement 1): 503.

https://doi.org/10.1182/blood-2025-503

Published: 2025

Journal Articles

A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41)

Andrew Yee, Elizabeth O'Donnell, Omar Nadeem, Garth Nelson, Tanya Wildes, Tondre Buck, Sascha Tuchman, Krishna Ghimire, Sarah Sinclair, Catherine Stewart, Paul Richardson, Saad Usmani, Noopur Raje

Blood (2025) 146 (Supplement 1): 4053.

https://doi.org/10.1182/blood-2025-4053

Published: 2025

Journal Articles

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Blood (2025) 146 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2025-4026

Published: 2025

Journal Articles

Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T.

Joshua Gustine, Narsis Attar, Benjamin Puliafito, Diana Cirstea, Andrew Branagan, Marcela Maus, Matthew Frigault, Andrew Yee, Noopur Raje

Blood (2025) 146 (Supplement 1): 5792.

https://doi.org/10.1182/blood-2025-5792

Published: 2025

Journal Articles

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

Blood (2025) 146 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2025-1533

Published: 2025

Journal Articles

First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance

Blood (2025) 146 (Supplement 1): 270.

https://doi.org/10.1182/blood-2025-270

Published: 2025

Journal Articles

Not in the beginning

Andrew Yee

Blood (2025) 146 (11): 1260–1261.

https://doi.org/10.1182/blood.2025029865

Published: 2025

Journal Articles

Tissue Kallikrein 1 and Alternative Complement Pathway Activation in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Sarah E Sartain, Paula Jacobi, Virginie Qian, Mrinal Ranjan, Saleh Bhar, Ang Li, Andrew Yee

Blood (2024) 144 (Supplement 1): 2604.

https://doi.org/10.1182/blood-2024-205948

Published: 2024

Journal Articles

Functional Assessment of VWD Type 2N Variants Using Mammalian Cell Displayed Surface-Tethered Von Willebrand Factor

Kerry W Lannert, Shelley N Fletcher, Nicholas A Popp, Pamela A Christopherson, Daniel J Hampshire, Doug M Fowler, Andrew Yee, Jill M Johnsen

Blood (2023) 142 (Supplement 1): 2604.

https://doi.org/10.1182/blood-2023-190788

Published: 2023

Journal Articles

Keeping it together

Andrew Yee

Blood (2023) 141 (12): 1374–1376.

https://doi.org/10.1182/blood.2022019547

Published: 2023

Journal Articles

Phage Display Functionally Defines Variants in the Von Willebrand Factor Platelet Binding Domain

Andrew Yee, Melda Arslantas Guzel, Manhong Dai, Fan Meng, David Ginsburg

Blood (2021) 138 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2021-151347

Published: 2021

Journal Articles

Comprehensive Genetic Interrogation of Circulating Multiple Myeloma Cells at Single Cell Resolution

Jens G Lohr, MD PhD, Sora Kim, Joshua Gould, Birgit Knoechel, MD PhD, Yotam Drier, PhD, Daniel Gray, PhD, Nicole Birrer, Bang Wong, Gavin Ha, PhD, Cheng-Zhong Zhang, PhD, Guangwu Guo, Matthew Meyerson, MD PhD, Andrew Yee, Jesse Boehm, PhD, Noopur Raje, MD, Todd R. Golub, MD

Blood (2016) 128 (22): 800.

https://doi.org/10.1182/blood.V128.22.800.800

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma

Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Immune aging and macrophage inhibitory factor (MIF) – mediated stromal rewiring drives pre-malignant evolution in smoldering multiple myeloma

Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma

Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma

A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41)

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T.

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance

Not in the beginning

Tissue Kallikrein 1 and Alternative Complement Pathway Activation in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Functional Assessment of VWD Type 2N Variants Using Mammalian Cell Displayed Surface-Tethered Von Willebrand Factor

Keeping it together

Phage Display Functionally Defines Variants in the Von Willebrand Factor Platelet Binding Domain

Comprehensive Genetic Interrogation of Circulating Multiple Myeloma Cells at Single Cell Resolution

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only